The 23andMe Research Institute bought the company's assets for $305 million, scotching a proposed sale to Regeneron ...

SAN FRANCISCO, CA / ACCESS Newswire / December 9, 2025 / Longwood Healthcare Leaders will convene top biopharmaceutical leaders at San Francisco CEO for two days of discussion, January 10-11, 2026, ...

Financing co-led by new investors, Ascenta Capital and Bessemer Venture PartnersAdditional new investors included YK Bioventures, Regeneron Ventures, Invus, and Finchley Healthcare Ventures, along ...

TSRA-196 is a potential one-time treatment to precisely correct the genetic mutation underlying AATD, with Investigational New Drug filing expected by the end of the year Tessera to receive $150 ...

Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 20 years by 14.96% on an annualized basis producing an average annual return of 23.64%. Currently, Regeneron ...

Bitcoin’s long-term design came under renewed scrutiny on Friday after VanEck CEO Jan van Eck questioned whether the network provides sufficient encryption and privacy during an appearance on CNBC’s ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The president and CEO of Insight ...

‘This was a personal decision I made earlier this year, and the board and I have been working together to make sure we handle this transition the right way. I’m incredibly proud of how this team has ...

Regeneron is expanding its pharmaceutical production in New York, joining a wave of drug companies growing domestic manufacturing in the wake of President Donald Trump’s tariffs. The move is a boon to ...

The year 2025 has been a time of unprecedented change for businesses. From fast-changing trade policies to ongoing inflation concerns to near-ubiquitous AI-driven transformations across industries, ...

Back from the 2025 American College of Allergy, Asthma & Immunology Annual Scientific Meeting, Dr S. Shahzad Mustafa recounts that a key focus was the management of urticaria and its significant ...